



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



FNDC7 siRNA (m): sc-145215

BACKGROUND

Fibronectins are multi-domain glycoproteins that bind to a variety of substances including collagen, Actin, heparin, DNA, fibrin and fibronectin receptors. Fibronectins are involved in a diverse array of important functions such as blood coagulation, wound healing, cell adhesion, cell differentiation and migration. Fibronectin type-III domain containing proteins, such as cell surface receptors and cell adhesion molecules, mediate protein-protein interactions and are involved in multiple biological processes including tissue development and metastasis. FNDC7 (fibronectin type III domain containing 7) is a 734 amino acid secreted protein containing eight fibronectin type-III domains. Conserved in human, chimpanzee, canine, bovine, mouse, rat, chicken and zebrafish, FNDC7 is encoded by a gene located on human chromosome 1p13.3. Human chromosome 1 spans 260 million base pairs, contains over 3,000 genes and comprises nearly 8% of the human genome.

REFERENCES

1. Kornblihtt, A.R., Umezawa, K., Vibe-Pedersen, K. and Baralle, F.E. 1985. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. *EMBO J.* 4: 1755-1759.
2. Leahy, D.J., Hendrickson, W.A., Aukhil, I. and Erickson, H.P. 1992. Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein. *Science* 258: 987-991.
3. Potts, J.R. and Campbell, I.D. 1994. Fibronectin structure and assembly. *Curr. Opin. Cell Biol.* 6: 648-655.
4. Little, E., Bork, P. and Doolittle, R.F. 1994. Tracing the spread of fibronectin type III domains in bacterial glycohydrolases. *J. Mol. Evol.* 39: 631-643.
5. Carr, P.A., Erickson, H.P. and Palmer, A.G. 1997. Backbone dynamics of homologous fibronectin type III cell adhesion domains from fibronectin and tenascin. *Structure* 5: 949-959.
6. Teufel, A., Malik, N., Mukhopadhyay, M. and Westphal, H. 2002. Frp1 and Frp2, two novel fibronectin type III repeat containing genes. *Gene* 297: 79-83.
7. Carafoli, F., Saffell, J.L. and Hohenester, E. 2008. Structure of the tandem fibronectin type 3 domains of neural cell adhesion molecule. *J. Mol. Biol.* 377: 524-534.
8. Bloom, L. and Calabro, V. 2009. FN3: a new protein scaffold reaches the clinic. *Drug Discov. Today* 14: 949-955.

CHROMOSOMAL LOCATION

Genetic locus: *Fndc7* (mouse) mapping to 3 F3.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

FNDC7 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see FNDC7 shRNA Plasmid (m): sc-145215-SH and FNDC7 shRNA (m) Lentiviral Particles: sc-145215-V as alternate gene silencing products.

For independent verification of FNDC7 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-145215A, sc-145215B and sc-145215C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

FNDC7 siRNA (m) is recommended for the inhibition of FNDC7 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor FNDC7 gene expression knockdown using RT-PCR Primer: FNDC7 (m)-PR: sc-145215-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.